We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients (AADC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02852213
Recruitment Status : Recruiting
First Posted : August 2, 2016
Last Update Posted : September 23, 2022
National Institute of Neurological Disorders and Stroke (NINDS)
University of California, San Francisco
Information provided by (Responsible Party):
Krzysztof Bankiewicz, Ohio State University

Brief Summary:
The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency.

Condition or disease Intervention/treatment Phase
AADC Deficiency Drug: AAV2-hAADC Phase 1

Detailed Description:

The Study will specifically address:

  • Safety, as measured by adverse events (AEs), safety laboratory tests, brain imaging, and the relationship of AEs to study/surgical procedures or to AAV2 hAADC.
  • Clinical responses to treatment with AAV2-hAADC. The primary clinical outcomes will reflect the predominant motor deficits of loss of motor function and dystonic movements.

Primary Endpoints Safety: Assessment of AE or severe AE (SAE) and its relationship to study surgery, infusion, or treatment effect (graded as definite, probable, possible, unlikely or unrelated).

  • Adverse Events and Serious Adverse Events
  • Post-operative MRI and/or CT (with contrast if clinically indicated)
  • Clinical laboratory assessments (hematology, chemistry, immunology) Biological Activity: Demonstration of effective restoration of AADC function by assays of cerebrospinal fluid (CSF) neurotransmitter metabolites and 18-fluoro-3,4-dihydroxyphenylalanine (F-DOPA) positron emission tomography (PET) imaging.

Secondary and Exploratory Endpoints To obtain preliminary data for clinical response by assessing the magnitude and variability of changes in specific outcomes.

The principal clinical outcome measures are:

  • Motor function, as assessed by the Gross Motor Function Measure (GMFM-88)
  • Frequency of oculogyric episodes, as measured by a Symptom Diary

Secondary clinical outcome measures include:

• Assessment of subject disability, as assessed using the Pediatric Evaluation of Disability Inventory (PEDI); adaptive behavior, as assessed using Vineland Adaptive Behavior Scale; Patient's Global Impression of Change (PGI-C); and quality of life, as determined using the Pediatric Quality of Life Inventory (PedsQL).

Although the investigators recognize that the utility of established developmental and cognitive assessments may be limited because of the study population's severe physical disability, the investigators will use the following:

  • Peabody Developmental Motor Scales 2nd edition (PDMS-2)
  • Bayley Scales of Infant Development, 3rd edition.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SIngle-Stage, Open-Label, Safety and Efficacy Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase by Magnetic Resonance MR-guided Infusion Into Midbrain in Pediatric Patients With AADC Deficiency
Study Start Date : July 2016
Estimated Primary Completion Date : January 2027
Estimated Study Completion Date : January 2030

Arm Intervention/treatment
Experimental: Single treatment arm

Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency.

6 subjects will be divided in 2 groups of 3. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes.

Subjects will be enrolled into 2 dose groups. Group 1 of 3 subjects will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dosing intervals will be 90 days between the first 3 subjects. Group 2 dosing level will be determined by Group 1 results.

Drug: AAV2-hAADC

Subjects will be enrolled sequentially into 2 dose groups, Group 1 followed by Group 2. Initially, up to 3 subjects initially will be enrolled in Group 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as an infusate volume of up to 160 μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Group 2 may commence after the last subject in Group 1 is treated and followed through Month 3 post-surgery, with the approval of the data safety monitoring board (DSMB).

The final safety and clinical outcome assessments will be performed 1 year post-surgery. A follow-up analysis will be performed for 2 years post-surgery. Thereafter, subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.

Other Name: Adeno Virus Human Aromatic L-Amino Acid Decarboxylase

Primary Outcome Measures :
  1. Adverse events related to surgery and gene transfer [ Time Frame: 2 years ]
    Assessment of adverse events related to surgery (including intracerebral hemorrhage or stroke, CNS infection) and gene transfer (including severity of post-operative dyskinesia)

  2. CSF neurotransmitter metabolite concentrations [ Time Frame: 1 year ]
    Change in CSF neurotransmitter metabolite concentrations after gene transfer (increase in homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), and elevated 3-O-methyldopa (3-OMD) concentrations)

Secondary Outcome Measures :
  1. Gross Motor Function Measure [ Time Frame: 2 years ]
    Increase in Gross Motor Function Measure-88 (GMFM-88) score

  2. Symptom Diary created by PI [ Time Frame: 1 years ]
    Decrease in frequency and severity of oculogyric episodes

  3. Fluorodopa PET scan [ Time Frame: Evaluated at 3 months and 2 years ]
    Increase in signal in the striatum on FDOPA-PET imaging as brain AADC activity measure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Definite diagnosis of AADC deficiency, confirmed by at least two of the following three criteria: (1) CSF neurotransmitter profile demonstrating reduced HVA and 5-HIAA, and elevated 3-OMD concentrations; (2) Plasma AADC activity less than or equal to 5 pmol/min/mL; (3) Molecular genetic confirmation of homozygous or compound heterozygous mutations in DDC.
  2. Age 4 years and up.
  3. Failed to derive adequate benefit from standard medical therapy (dopamine agonists, monoamine oxidase inhibitor, pyridoxine or related form of Vitamin B6).
  4. Unable to ambulate independently (with or without assistive device).
  5. Cranium sufficiently developed, with sutures closed, to enable surgical placement of SmartFrame® system on the skull for MRI-guided stereotactic targeting.
  6. Brain MRI does not show any conditions or malformations that are clinically significant with respect to risks for stereotactic brain surgery.
  7. Parent(s)/legal guardian(s) of the subject must agree to comply with the requirements of the study, including the need for frequent and prolonged follow-up.
  8. Parent(s)/legal guardian(s) with custody of subject must give their consent for subject to enroll in the study.
  9. Stable medication regimen for treatment of AADC deficiency: (i.e. no new medications introduced for at least 6 months, and no existing medication dose changes for at least 3 months prior to Baseline).
  10. Baseline hematology, chemistry, and coagulation values within the normal pediatric laboratory value ranges, unless in the Investigator's judgment, the out of range values are not clinically significant with respect to subject's suitability for surgery.

Exclusion Criteria

  1. Intracranial neoplasm or any structural brain abnormality or lesion (e.g., severe brain atrophy, white matter degenerative changes), which, in the opinion of the study investigators, would confer excessive risk and/or inadequate potential for benefit.
  2. Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk (including congenital heart disease, respiratory disease with home oxygen requirement, history of serious anesthesia complications during previous elective procedures, history of cardiorespiratory arrest), liver or renal failure, malignancy, or HIV positive.
  3. Previous stereotactic neurosurgery.
  4. Coagulopathy, or need for ongoing anticoagulant therapy.
  5. Contraindication to sedation during surgery or imaging studies (SPECT, PET or MRI).
  6. Receipt of any investigational agent within 60 days prior to Baseline and during study participation.
  7. Evidence of clinically active infection with adenovirus or herpes virus on physical examination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02852213

Layout table for location contacts
Contact: Andrea Davis, MS 614-688-6412 andrea.hesse@osumc.edu
Contact: Waldy San Sebastian, PhD Waldy.SanSebastian@ucsf.edu

Layout table for location information
United States, California
University of California San Francisco, Benioff Children's Hospital Active, not recruiting
San Francisco, California, United States, 94143
United States, Ohio
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: Hannah Lehmann       hannah.lehmann@nationwidechildrens.org   
Principal Investigator: Jeffrey Leonard, MD         
The Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43221
Contact: Andrea Davis, MS    614-688-6412    andrea.hesse@osumc.edu   
Principal Investigator: Russell Lonser, MD         
Principal Investigator: Krystof Bankiewicz         
Sponsors and Collaborators
Krzysztof Bankiewicz
National Institute of Neurological Disorders and Stroke (NINDS)
University of California, San Francisco
Layout table for investigator information
Principal Investigator: Krystof Bankiewicz, MD, PhD OSU Professor of Neurological Surgery
  Study Documents (Full-Text)

Documents provided by Krzysztof Bankiewicz, Ohio State University:
Haley, S., W. Coster, L. Ludlow, J. Haltiwanger and A. PA (1992). Pediatric Evaluation of Disability Inventory: Development, Standardization and Administration Manual. Boston, MA, Trustees of Boston University.
Russell, D. J., P. L. Rosenbaum, L. M. Avery and M. Lane (2002). The Gross Motor Function Measure (GMFM-66 & GMFM-88) User's Manual. London, Mac Keith Press.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Krzysztof Bankiewicz, Professor of Neurological Surgery, Ohio State University
ClinicalTrials.gov Identifier: NCT02852213    
Other Study ID Numbers: 2018H0269
1R01NS094292-03 ( U.S. NIH Grant/Contract )
First Posted: August 2, 2016    Key Record Dates
Last Update Posted: September 23, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The investigators will share pertinent information with the subjects care team such that standard of care for the subject can be maintained.
Supporting Materials: Clinical Study Report (CSR)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Krzysztof Bankiewicz, Ohio State University:
gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Dopa Decarboxylase
Antiparkinson Agents
Anti-Dyskinesia Agents